Optimising the vaccine strategy of BCG, ChAdOx185A, and MVA85A for tuberculosis control

被引：4
作者：
Gong, Wenping [1 ]
Du, Jingli [1 ]
机构：
[1] Eighth Med Ctr PLA Gen Hosp, Senior Dept TB, Beijing Key Lab New Tech TB Diag & Treatment, Beijing 100091, Peoples R China
来源：
LANCET INFECTIOUS DISEASES | 2024年 / 24卷 / 03期
关键词：
D O I：
10.1016/S1473-3099(23)00514-5
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：224 / 226
页数：3
相关论文
共 11 条
  • [1] The success and failure of BCG - implications for a novel tuberculosis vaccine
    Andersen, P
    Doherty, TM
    [J]. NATURE REVIEWS MICROBIOLOGY, 2005, 3 (08) : 656 - 662
  • [2] BCG scarring and improved child survival: a combined analysis of studies of BCG scarring
    Benn, C. S.
    Roth, A.
    Garly, M-L
    Fisker, A. B.
    Schaltz-Buchholzer, F.
    Timmermann, A.
    Berendsen, M.
    Aaby, P.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2020, 288 (06) : 614 - 624
  • [3] Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
  • [4] Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development
    Hu, Zhidong
    Lu, Shui-Hua
    Lowrie, Douglas B.
    Fan, Xiao-Yong
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
    Pinpathomrat, Nawamin
    Bull, Naomi
    Pasricha, Janet
    Harrington-Kandt, Rachel
    McShane, Helen
    Stylianou, Elena
    [J]. VACCINE, 2021, 39 (09) : 1452 - 1462
  • [6] Protection against tuberculosis by Bacillus Calmette-Guerin (BCG) vaccination: A historical perspective
    Setiabudiawan, Todia P.
    Reurink, Remi K.
    Hill, Philip C.
    Netea, Mihai G.
    van Crevel, Reinout
    Koeken, Valerie A. C. M.
    [J]. MED, 2022, 3 (01): : 6 - 24
  • [7] Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
    Stylianou, E.
    Griffiths, K. L.
    Poyntz, H. C.
    Harrington-Kandt, R.
    Dicks, M. D.
    Stockdale, L.
    Betts, G.
    McShane, H.
    [J]. VACCINE, 2015, 33 (48) : 6800 - 6808
  • [8] Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
    Tameris, Michele D.
    Hatherill, Mark
    Landry, Bernard S.
    Scriba, Thomas J.
    Snowden, Margaret Ann
    Lockhart, Stephen
    Shea, Jacqueline E.
    McClain, J. Bruce
    Hussey, Gregory D.
    Hanekom, Willem A.
    Mahomed, Hassan
    McShane, Helen
    [J]. LANCET, 2013, 381 (9871) : 1021 - 1028
  • [9] Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth a randomised, open-label trial
    Wajja, Anne
    Nassanga, Beatrice
    Natukunda, Agnes
    Serubanja, Joel
    Tumusiime, Josephine
    Akurut, Helen
    Oduru, Gloria
    Nassuuna, Jacent
    Kabagenyi, Joyce
    Morrison, Hazel
    Scott, Hannah
    Doherty, Rebecca Powell
    Marshall, Julia L.
    Puig, Ingrid Cabrera
    Cose, Stephen
    Kaleebu, Pontiano
    Webb, Emily L.
    Satti, Iman
    McShane, Helen
    Elliott, Alison M.
    [J]. LANCET INFECTIOUS DISEASES, 2024, 24 (03) : 285 - 296
  • [10] A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost in healthy UK adults
    Wilkie, Morven
    Satti, Iman
    Minhinnick, Alice
    Harris, Stephanie
    Riste, Michael
    Ramon, Raquel Lopez
    Sheehan, Sharon
    Thomas, Zita-Rose Manjaly
    Wright, Daniel
    Stockdale, Lisa
    Hamidi, Ali
    O'Shea, Matthew K.
    Dwivedi, Kritica
    Behrens, Hannah Michaela
    Davenne, Tamara
    Morton, Joshua
    Vermaak, Samantha
    Lawrie, Alison
    Moss, Paul
    McShane, Helen
    [J]. VACCINE, 2020, 38 (04) : 779 - 789
12